Lipum AB (publ) has carried out a directed share issue

Lipum has carried out a directed share issue of approximately SEK 39 million to certain existing and new investors with pronounced long-term interests in the company.

The proceeds will be used primarily to finance the company’s phase I study and for extended pre-clinical studies of the biological drug candidate SOL-116.

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). Lipum’s shares are listed on Nasdaq First North Growth Market (LIPUM).

Lipum was represented by Mannheimer Swartling in the transaction.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.